JP2016536568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536568A5 JP2016536568A5 JP2016515521A JP2016515521A JP2016536568A5 JP 2016536568 A5 JP2016536568 A5 JP 2016536568A5 JP 2016515521 A JP2016515521 A JP 2016515521A JP 2016515521 A JP2016515521 A JP 2016515521A JP 2016536568 A5 JP2016536568 A5 JP 2016536568A5
- Authority
- JP
- Japan
- Prior art keywords
- autoantibodies
- ovarian cancer
- autoantibody
- subject
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903595A AU2013903595A0 (en) | 2013-09-18 | Autoantibody biomarkers of ovarian cancer | |
| AU2013903595 | 2013-09-18 | ||
| PCT/AU2014/000925 WO2015039175A1 (en) | 2013-09-18 | 2014-09-18 | Autoantibody biomarkers of ovarian cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536568A JP2016536568A (ja) | 2016-11-24 |
| JP2016536568A5 true JP2016536568A5 (enExample) | 2017-10-26 |
| JP6588893B2 JP6588893B2 (ja) | 2019-10-09 |
Family
ID=52687999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515521A Active JP6588893B2 (ja) | 2013-09-18 | 2014-09-18 | 卵巣がんの自己抗体バイオマーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20160291025A1 (enExample) |
| EP (1) | EP3047277B1 (enExample) |
| JP (1) | JP6588893B2 (enExample) |
| CN (1) | CN105745543B (enExample) |
| AU (1) | AU2014324080B2 (enExample) |
| CA (1) | CA2924600A1 (enExample) |
| WO (1) | WO2015039175A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107056888A (zh) * | 2017-03-01 | 2017-08-18 | 中山大学肿瘤防治中心 | Atp1a1靶向多肽及应用 |
| CN109116024B (zh) * | 2018-06-14 | 2021-04-23 | 郑州大学第一附属医院 | 一种肺癌标志物抗-actr3自身抗体及其应用 |
| GB201813137D0 (en) | 2018-08-10 | 2018-09-26 | Medannex Ltd | Cancer treatment with an antibody |
| CN109182260A (zh) * | 2018-09-11 | 2019-01-11 | 邵勇 | 一种体外培养胎膜间充质干细胞的方法 |
| CN109480771B (zh) * | 2018-10-17 | 2021-09-07 | 江西惠肽生物科技有限公司 | 一种卵巢肿块良恶的确定方法及确定装置 |
| JP2022522803A (ja) * | 2019-03-01 | 2022-04-20 | アドバンスド マーカー ディスカバリー エセ． エレ． | 結腸直腸癌及び／又はその前癌段階の診断用タンパク質シグネチャー |
| CA3155018A1 (en) * | 2019-10-16 | 2021-04-22 | John Martignetti | Systems and methods for detecting a disease condition |
| US12152280B2 (en) | 2021-09-20 | 2024-11-26 | Droplet Biosciences, Inc. | Drain fluid for diagnostics |
| CA3245623A1 (en) * | 2022-03-10 | 2023-09-14 | The Hospital For Sick Children | DIAGNOSIS OF CONGENITAL HEART BLOCK |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002539175A (ja) * | 1999-03-15 | 2002-11-19 | ユニバーシティ・オブ・メリーランド・ボルティモア | 癌細胞において表面に存在するコリジン／Ｈｓｐ４７ |
| US6645465B2 (en) * | 1999-08-06 | 2003-11-11 | Michigan, University Of The Regents | Annexin proteins and autoantibodies as serum markers for cancer |
| US20020037286A1 (en) * | 2000-04-03 | 2002-03-28 | Matthias Krause | Methods for altering T cell and macrophage activation |
| US8614169B2 (en) * | 2001-12-04 | 2013-12-24 | Wayne State University | Neoepitope detection of disease using protein arrays |
| DE60332639D1 (de) * | 2002-08-06 | 2010-07-01 | Univ Johns Hopkins | Verwendung von biomarkern zum nachweis von eierstockkrebs |
| CN101268367A (zh) * | 2005-06-24 | 2008-09-17 | 赛弗吉生物系统公司 | 卵巢癌的生物标记 |
| JP2009524438A (ja) * | 2006-01-27 | 2009-07-02 | トライパス イメージング インコーポレイテッド | 卵巣癌を有する可能性の高い患者を同定するための方法およびそのための組成物 |
| CA2663154C (en) * | 2006-09-13 | 2016-02-23 | Oncimmune Ltd | Improved immunoassay methods |
| WO2008115710A2 (en) * | 2007-03-07 | 2008-09-25 | The Johns Hopkins University | Biomarkers for cancer |
| JP5265140B2 (ja) * | 2007-06-14 | 2013-08-14 | 学校法人日本医科大学 | 卵巣癌の検出方法及び検出用キット |
| WO2009006439A1 (en) * | 2007-06-29 | 2009-01-08 | Correlogic Systems, Inc. | Predictive markers for ovarian cancer |
| RU2508114C2 (ru) * | 2007-11-13 | 2014-02-27 | Феникс Байотекнолоджи Инк. | Способ определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом |
| EP2277049A4 (en) * | 2008-05-09 | 2012-05-30 | Univ Duke | AUTOANTIKÖRPER FOR THE PROOF AND THE TREATMENT OF CANCER |
| US20120046181A1 (en) * | 2008-12-19 | 2012-02-23 | Chu Nantes | Biomarkers for the Diagnosis of Renal Allograft and Kidney Status |
| US20120004289A1 (en) * | 2009-03-06 | 2012-01-05 | The Johns Hopkins University | Annexin a11 and associated genes as biomarkers for cancer |
| CN101762699A (zh) * | 2009-06-24 | 2010-06-30 | 北京科美东雅生物技术有限公司 | 一种定量检测血液中肿瘤相关抗原125的磁性免疫层析试纸条及制备方法 |
| US20120277326A1 (en) | 2009-11-20 | 2012-11-01 | Taylor Douglas D | Biomarkers of cancer |
| JP2011257147A (ja) * | 2010-06-04 | 2011-12-22 | Nitto Boseki Co Ltd | データ収集方法、キット及び腫瘍マーカー |
| JP6205621B2 (ja) * | 2012-01-26 | 2017-10-04 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | 抗体を有するインターフェロンλでの標的化は抗腫瘍および抗ウイルス活性を大きく増強する |
| CN102590531A (zh) * | 2012-03-24 | 2012-07-18 | 广西壮族自治区肿瘤防治研究所 | 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法 |
| JP5574348B2 (ja) * | 2012-05-31 | 2014-08-20 | 国立大学法人 千葉大学 | 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット |
| US20140179808A1 (en) * | 2012-10-23 | 2014-06-26 | Bio-Rad Laboratories, Inc. | Detection of Ovarian Carcinoma by Assay for Autoantibodies to Multiple Antigens |
| CA2894538A1 (en) | 2013-01-31 | 2014-08-07 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Ari | Autoantibody signature for the early detection of ovarian cancer |
-
2014
- 2014-09-18 WO PCT/AU2014/000925 patent/WO2015039175A1/en not_active Ceased
- 2014-09-18 EP EP14846089.2A patent/EP3047277B1/en active Active
- 2014-09-18 US US15/023,155 patent/US20160291025A1/en not_active Abandoned
- 2014-09-18 CA CA2924600A patent/CA2924600A1/en not_active Abandoned
- 2014-09-18 JP JP2016515521A patent/JP6588893B2/ja active Active
- 2014-09-18 CN CN201480063118.7A patent/CN105745543B/zh active Active
- 2014-09-18 AU AU2014324080A patent/AU2014324080B2/en active Active
-
2019
- 2019-01-11 US US16/245,822 patent/US11371993B2/en active Active
-
2022
- 2022-05-27 US US17/826,948 patent/US12287337B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Hepatocellular carcinoma: old friends and new tricks | |
| Costantini et al. | Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab | |
| Hu et al. | CLEC1B expression and PD-L1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage | |
| Wan et al. | New labyrinth microfluidic device detects circulating tumor cells expressing cancer stem cell marker and circulating tumor microemboli in hepatocellular carcinoma | |
| Sadeghi et al. | Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma | |
| Wang et al. | Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer | |
| ES2355388T3 (es) | Métodos para la detección precoz de cáncer. | |
| Zhu et al. | B7-H4 expression is associated with cancer progression and predicts patient survival in human thyroid cancer | |
| Rubie et al. | Enhanced expression and clinical significance of CC‐chemokine MIP‐3α in hepatocellular carcinoma | |
| Duan et al. | Genetic biomarkers for hepatocellular carcinoma in the era of precision medicine | |
| Bahnassy et al. | Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data | |
| Wimberger et al. | Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer | |
| Frick et al. | CCR 6/CCL 20 Chemokine Expression Profile in Distinct Colorectal Malignancies | |
| Maxwell et al. | A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors | |
| Usó et al. | Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers | |
| Cha et al. | EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinoma | |
| Otterstrom et al. | CD74: a new prognostic factor for patients with malignant pleural mesothelioma | |
| Li et al. | Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study | |
| Li et al. | CCL 20‐CCR 6 Cytokine Network Facilitate Treg Activity in Advanced Grades and Metastatic Variants of Hepatocellular Carcinoma | |
| Sun et al. | Expression of HGF and Met in human tissues of colorectal cancers: biological and clinical implications for synchronous liver metastasis | |
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| Duan et al. | Microfluidic immunoassay system for rapid detection and semi-quantitative determination of a potential serum biomarker mesothelin | |
| Mink et al. | Evaluation of nectin-4 and trop-2: implications for patient outcomes and therapy in penile cancer | |
| Carrasco-Torres et al. | The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker | |
| RU2016135933A (ru) | Композиция для противоракового вспомогательного лекарственного средства, содержащая средство, индуцирующее экспрессию rip3, в качестве активного ингредиента, способ скрининга противоракового вспомогательного лекарственного средства, повышающего чувствительность к противораковому лекарственному средству путем стимуляции экспрессии rip3, и способ контроля чувствительности к противораковому лекарственному средству |